Navigation Links
Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
Date:1/9/2012

ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 2012 Biotech Showcase in San Francisco on Tuesday, January 10, 1:45-3:00pm PT. Garr will serve on the Therapeutic Focus Panel entitled, "Neurodegenerative Disease, Ophthalmology and Spinal Injury," featured in the Alliance for Regenerative Medicine (ARM) Insight Track. Garr will also present a business overview, including an update on the world's first FDA-approved stem cell injections in the cervical region, in its ongoing ALS cell therapy Phase I trial. He will also present an update on the recently FDA-approved advancement to Phase Ib dosing in depressed patients of its first-in-class NSI-189 small molecule drug, in its ongoing NSI-189/major depressive disorder (MDD) trial.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Biotech Showcase will be held at the Parc 55 Wyndham Hotel in San Francisco, January 9-11. For more information, see: http://www.ebdgroup.com/bts/index.php. Biotech Showcase runs concurrently to the world's largest annual healthcare investor conference, and provides private and public life science companies the opportunity to present to an audience of investors and business development executives interested in innovative biotech companies.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosi
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
3. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
4. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
5. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
6. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
7. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
8. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
9. Neuralstem Completes $5.25 Million Financing
10. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
11. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The ability to see through organs and even the ... well as fine-grained cellular structures has been a long-time ... Press July 31st in the journal Cell ... simple methods for making opaque organs, bodies, and human ... connections intact. The protocols could pave the way for ...
(Date:7/31/2014)... Colo. , July 31, 2014 ... awardee today with $25,000 to fund a translational ... inception in 2011, the gift was presented at ... Annual Meeting in Colorado Springs, ... specialize in neurointerventional approaches to neurovascular conditions, SNIS ...
(Date:7/31/2014)... 2014 Graphite Metallizing Corporation announces ... carts. These bearings are uniquely suited to prevent loss ... because of the high temperatures . , Recently, ... the design engineers at Graphite Metallizing to overcome problems ... their manufacturing operation, pans containing blocks of powder mixture ...
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... of Magainins, the first of a new class of anti-infectives, ... advise Company on pexiganan ... Bulletin Board: MACM) today announced that following its,acquisition of rights ... Board. Dr. Zasloff discovered magainins in,the skin of the African ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
... Kyphon Inc.,(Nasdaq: KYPH ) announced today that its ... Inc. (NYSE: MDT ) at a special,meeting of ... 26, 2007, Kyphon entered into a,definitive merger agreement with ... the outstanding shares of Kyphon common stock for,$71.00 per ...
Cached Biology Technology:MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 2MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 4MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 5Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2Kyphon Stockholders Approve Merger with Medtronic 2
(Date:7/31/2014)... United States, natural-gas production from shale rock has ... Yet scientists still do not fully understand the ... a report in the journal Frontiers in ... extraction continues to vastly outpace scientific examination, a ... and institutions, including Princeton University, concluded that determining ...
(Date:7/31/2014)... nearly 3,000 genes to the earliest common ancestor ... have created an extensive "Tree of Lepidoptera" in ... sequencing. , Among the study,s more surprising ... moths than to large ones, which completely changes ... also found that some insects once classified as ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
Breaking Biology News(10 mins):'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... ANN ARBOR, Mich.---University of Michigan School of Dentistry has ... may be the largest clinical study to date using genetic ... William Giannobile, professor at U-M dentistry and director of the ... Dentistry, will lead the study for U-M. "It,s ...
... and Building Media Inc. (BMI), a DuPont subsidiary, will ... help dramatically improve the energy efficiency of American homes ... 15 teams, appointed by the U.S. Department of Energy ... million for the initial 18 months to deliver innovative ...
... July 27, 2010 Innovotech Inc. (TSX-V: IOT), a pioneer ... exclusive distribution agreement with LevPharm Ltd of Israel to market ... within Israel. "We are very excited to enter into ... bioFILM PA test can have on improving patient care while ...
Cached Biology News:Landmark dental school study uses genetic test to help predict gum disease 2NJIT to help lead public/private partnership to develop high-efficiency homes 2
KAI 1 (G-2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Biology Products: